X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Dishman Pharma with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs TEVA PHARMA (Israel) - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DISHMAN PHARMA   TEVA PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
TEVA PHARMA
Dec-13
DISHMAN PHARMA/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs3742,683-   
Low Rs1292,330-   
Sales per share (Unadj.) Rs197.81,539.6-  
Earnings per share (Unadj.) Rs21.296.2-  
Cash flow per share (Unadj.) Rs34.7220.6-  
Dividends per share (Unadj.) Rs2.0084.19-  
Dividend yield (eoy) %0.83.4 23.7%  
Book value per share (Unadj.) Rs179.91,710.2-  
Shares outstanding (eoy) m80.69848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.31.6 78.1%   
Avg P/E ratio x11.926.1 45.5%  
P/CF ratio (eoy) x7.211.4 63.8%  
Price / Book Value ratio x1.41.5 95.4%  
Dividend payout %9.487.5 10.8%   
Avg Mkt Cap Rs m20,3062,125,537 1.0%   
No. of employees `0000.844.9 1.8%   
Total wages/salary Rs m5,3550-   
Avg. sales/employee Rs Th19,252.729,048.4 66.3%   
Avg. wages/employee Rs Th6,459.50-   
Avg. net profit/employee Rs Th2,064.11,814.6 113.7%   
INCOME DATA
Net Sales Rs m15,9611,305,581 1.2%  
Other income Rs m2650-   
Total revenues Rs m16,2261,305,581 1.2%   
Gross profit Rs m4,103357,534 1.1%  
Depreciation Rs m1,091105,531 1.0%   
Interest Rs m94425,644 3.7%   
Profit before tax Rs m2,334226,359 1.0%   
Minority Interest Rs m01,028 0.0%   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m0-148,592 0.0%   
Tax Rs m624-2,764 -22.6%   
Profit after tax Rs m1,71181,559 2.1%  
Gross profit margin %25.727.4 93.9%  
Effective tax rate %26.7-1.2 -2,188.8%   
Net profit margin %10.76.2 171.6%  
BALANCE SHEET DATA
Current assets Rs m11,018881,784 1.2%   
Current liabilities Rs m9,517768,991 1.2%   
Net working cap to sales %9.48.6 108.8%  
Current ratio x1.21.1 101.0%  
Inventory Days Days11091 121.7%  
Debtors Days Days3596 36.3%  
Net fixed assets Rs m16,304426,431 3.8%   
Share capital Rs m1613,214 5.0%   
"Free" reserves Rs m12,9070-   
Net worth Rs m14,5161,450,253 1.0%   
Long term debt Rs m4,189667,572 0.6%   
Total assets Rs m29,8052,983,670 1.0%  
Interest coverage x3.59.8 35.3%   
Debt to equity ratio x0.30.5 62.7%  
Sales to assets ratio x0.50.4 122.4%   
Return on assets %8.93.6 248.0%  
Return on equity %11.85.6 209.6%  
Return on capital %17.54.9 355.5%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Net fx Rs m4,2550-   
CASH FLOW
From Operations Rs m2,786208,042 1.3%  
From Investments Rs m-1,529-73,718 2.1%  
From Financial Activity Rs m-941-249,560 0.4%  
Net Cashflow Rs m316-115,236 -0.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 64.27 Rs / USD

Compare DISHMAN PHARMA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  

Compare DISHMAN PHARMA With: IPCA LABS  DIVIS LABORATORIES  ALKEM LABORATORIES  GLENMARK PHARMA  ALEMBIC LTD  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - STRIDES SHASUN LTD COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS